Retatrutide is one of the most aggressive obesity drugs ever tested in clinical trials. In a Phase 2 study, people with obesity lost more than 24% of their starting body weight in under a year at higher doses, a level of weight loss that rivals bariatric surgery outcomes for some patients.
It is not approved. You cannot legitimately get it from a pharmacy, med spa, or “research peptide” website. It is still an investigational drug undergoing clinical trials.
But for any clinic working with GLP-1 therapies, advanced lab testing, and functional medicine, retatrutide is a clear signal of where obesity and metabolic care are going.
This article breaks down what retatrutide is, how it works, what the most recent research actually shows, how it compares to semaglutide and tirzepatide, and how a functional medicine model like 1st Optimal would integrate drugs like this into a complete weight loss and longevity strategy once they are approved.
What is retatrutide?
Retatrutide (LY3437943) is an investigational injectable peptide being developed for obesity, type 2 diabetes, and metabolic liver disease. It belongs to a new class of drugs called triple agonists: it activates three different hormone receptors involved in appetite, blood sugar, and energy expenditure.
Retatrutide targets:
- GLP-1 (glucagon-like peptide-1) receptors
- GIP (glucose-dependent insulinotropic polypeptide) receptors
- Glucagon receptors
This “triple hit” is designed to:
- Reduce appetite and food intake
- Improve insulin secretion and sensitivity
- Shift metabolism toward greater energy use and fat burning
Phase 2 trials suggest that this triple agonist approach can drive faster and deeper weight loss than earlier single or dual incretin drugs.
How retatrutide works: triple agonist mechanism
To understand retatrutide, you have to zoom out to incretin biology.
GLP-1: satiety and glucose control
GLP-1 is a gut hormone released after meals. It:
- Increases insulin secretion when glucose is high
- Decreases glucagon secretion when appropriate
- Slows stomach emptying
- Signals satiety to the brain
Drugs like semaglutide and liraglutide are GLP-1 receptor agonists. They essentially “boost” the normal GLP-1 signal so you feel full sooner, eat less, and improve blood sugar control.
GIP: insulin and fat metabolism
GIP is another incretin hormone that:
- Enhances insulin secretion
- Interacts with adipose tissue and lipid metabolism
- Affects appetite when pharmacologically activated
Tirzepatide already combines GLP-1 and GIP agonism and has shown greater weight loss than GLP-1 alone.
Glucagon: energy expenditure and fat mobilization
Glucagon is often thought of as the “opposite of insulin” because it raises blood sugar. But it also:
- Increases energy expenditure
- Promotes breakdown of fat stores
- Influences liver metabolism
In animal and human studies, combining glucagon receptor agonism with GLP-1 (and now GIP) seems to drive both lower food intake and higher calorie burn, which is how retatrutide can produce such large changes in body weight.
Retatrutide is engineered to balance these three signals so that you get:
- Less hunger
- Better blood sugar
- More fat oxidation and energy expenditure
while trying to keep side effects manageable.
Clinical trial results: how much weight do people actually lose?
The trial that put retatrutide on the map was a Phase 2, randomized, placebo-controlled study in adults with obesity, published in the New England Journal of Medicine in 2023.
Key points:
- 338 adults with obesity (no diabetes) were enrolled.
- Participants received weekly injections of retatrutide or placebo for 48 weeks.
- Doses ranged from 1 mg to 12 mg.
Weight loss results:
- At 24 weeks, average weight loss ranged from about 7% (1 mg) up to about 17.5% in the highest-dose group, compared with −1.6% in the placebo group.
- At 48 weeks, participants on 8 mg and 12 mg doses lost on average around 22.8% and 24.2% of their starting body weight.
To put that into real numbers:
For someone starting at 230 pounds, 24% weight loss is about 55 pounds in under a year.
Other trials show similar patterns:
- In people with type 2 diabetes, retatrutide produced large reductions in A1c and robust weight loss, with a safety profile consistent with other incretin-based drugs.
Bottom line: based on current data, retatrutide produces some of the largest average weight-loss changes ever documented in a drug trial that did not involve surgery.
Retatrutide vs semaglutide vs tirzepatide
Many people want a simple ranking: which one is “strongest”?
Direct head-to-head trials do not exist yet, so any comparison is indirect, but we can look at ballpark numbers from major clinical trials:
- Semaglutide 2.4 mg (Wegovy) in obesity: about 14–15% average weight loss over 68 weeks.
- Tirzepatide (Zepbound) in obesity: about 20–22.5% average weight loss over 72 weeks.
- Retatrutide in Phase 2 obesity trial: roughly 22.8–24.2% average weight loss over 48 weeks at higher doses.
Those trials differ in design, follow-up, and populations, so you cannot treat them like a perfect “apples to apples” comparison. But it is reasonable to say:
Retatrutide appears to be at least as potent as tirzepatide, and likely more potent than semaglutide, for body-weight reduction when used at the higher studied doses.
With higher potency usually comes:
- Stronger benefits for body weight and metabolic disease
- Higher risk of side effects if not carefully titrated
- Greater need for clinical supervision and comprehensive support
Retatrutide would almost certainly be a “serious tool for serious cases,” not a casual first-line weight loss drug.
Liver and metabolic benefits beyond the scale
Body weight is only part of the story.
A 2024 trial in Nature Medicine looked at retatrutide in people with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD, previously called NAFLD).
In that study:
- Retatrutide led to large, clinically meaningful reductions in liver fat.
- Some participants experienced up to an 82% relative reduction in liver fat content.
- Liver enzymes and other markers of metabolic health also improved.
This suggests that retatrutide may eventually play a role not only in obesity treatment but also in metabolic liver disease, which is extremely common in people with central obesity, insulin resistance, and elevated triglycerides.
From a functional medicine perspective, this matters because:
- MASLD is now one of the most common liver diseases worldwide.
- It is tightly linked to insulin resistance, visceral fat, and cardiometabolic risk.
- Drugs that improve both body weight and liver health fit perfectly into a systems-level strategy for long-term disease prevention.
Effects on body composition and energy expenditure
Weight loss is not just about the scale; it is about what you are losing.
An emerging substudy in The Lancet Diabetes & Endocrinology examined changes in body composition on retatrutide. Early data suggest:
- Significant reductions in total body fat mass
- Meaningful reductions in visceral (deep abdominal) fat
- Smaller relative losses in lean mass compared to fat mass, especially when weight loss is paired with resistance training and adequate protein intake
Preclinical and human data also support that glucagon receptor activation increases resting energy expenditure, which means part of retatrutide’s effect may be driven by a true boost in metabolic rate rather than calorie restriction alone.
For a clinic focused on performance and muscle preservation, like 1st Optimal, this is crucial: the goal is not just weight loss; it is better body composition, metabolic flexibility, and functional strength.
Side effects, risks, and what we still do not know
Retatrutide’s side effect profile looks broadly similar to other incretin-based drugs, especially at higher doses.
The most common side effects in trials include:
- Nausea
- Vomiting
- Diarrhea or constipation
- Abdominal pain or discomfort
- Loss of appetite
- Injection site reactions
Most side effects appeared during dose escalation and were managed by gradual titration and dose adjustments.
Signals and unknowns that need longer follow-up:
- Modest increases in heart rate (several beats per minute on average) have been observed, similar to other GLP-1–based therapies.
- Risk of gallbladder-related problems (which has been seen with other GLP-1 drugs).
- Long-term cardiovascular, pancreatic, and liver outcomes are not fully known yet because Phase 3 outcome trials are still underway.
We also do not know:
- The best long-term maintenance dose
- How weight maintenance looks over multiple years after initial loss
- Whether some patients will be more prone to side effects due to genetics, comorbidities, or concurrent therapies
As with any powerful medication, the early data are impressive, but they are not the final word.
Is retatrutide available now? (And why “research peptide” versions are a problem)
Retatrutide is not FDA-approved for weight loss, diabetes, or liver disease at this time. It is still an investigational agent undergoing clinical development.
Despite this, there are already websites and “research chemical” vendors claiming to sell retatrutide directly to consumers. Regulatory agencies have started to respond:
- The FDA has warned about illegally marketed, unapproved GLP-1 products that include semaglutide, tirzepatide, and retatrutide, often labeled “for research purposes only” or “not for human consumption” but clearly promoted for self-injection.
- News investigations in Europe have found retatrutide being sold on black markets and social media, with people injecting unknown products outside any medical supervision.
These problems are not small details. They mean:
- You have no guarantee the vial actually contains retatrutide.
- Dose may be wildly incorrect.
- Sterility and purity are unknown.
- Side effects are harder to manage without medical oversight.
Any legitimate use of retatrutide today is happening inside controlled clinical trials, not in private compounding, not in med spas, and not in online “biohacking” channels.
For a clinic that values evidence, quality, and patient safety, this is non-negotiable.
How 1st Optimal uses GLP-1 therapies today
Even without retatrutide on the market, the underlying strategy it represents is already in use: multi-pathway metabolic optimization built on a foundation of labs, coaching, and long-term planning.
A high-touch functional medicine approach to GLP-1 therapies at 1st Optimal typically includes:
- Comprehensive lab testing
- Fasting glucose, insulin, and HbA1c
- Lipid profile and advanced lipoprotein markers
- Liver enzymes and, if needed, imaging for MASLD
- Thyroid panel
- Sex hormones and cortisol
- Inflammatory markers and nutrient status
- Nutrition built around muscle protection and metabolic stability
- High protein targets
- Smart carb rotation or calorie cycling
- Fiber and gut-support strategies
- Adequate micronutrients
- Training programs matched to the medication
- Resistance training to preserve or build lean mass
- Zone 2 and conditioning for cardiovascular health
- Recovery planning to prevent overtraining on lower calories
- Hormone optimization
- Addressing estrogen, progesterone, and testosterone in midlife
- Correcting thyroid dysfunction
- Supporting adrenal balance
- Peptide and adjunct therapies
- Where appropriate and evidence-based
- Always layered into a monitored, lab-driven plan
When a drug as strong as retatrutide eventually becomes available, it will not replace this structure. It will sit inside it.
Who might be a good candidate in the future?
If and when retatrutide is approved, likely candidates may include:
- Adults with obesity (BMI ≥ 30)
- Adults with BMI ≥ 27 and obesity-related conditions like type 2 diabetes, MASLD, or sleep apnea
- People who have not responded enough to first-line GLP-1 or dual agonist therapy
- Patients with high cardiometabolic risk who need meaningful weight loss but are not candidates for surgery
For a clinic like 1st Optimal, the ideal fit would likely be:
- High-achieving adults 35–55 whose weight and metabolic health are holding them back
- People ready to commit to lab-based care, structured nutrition, and training
- Patients who understand that a drug like retatrutide is a powerful tool inside a system, not a quick fix
This is where the future of obesity medicine is heading: precision drug selection inside complete, personalized metabolic programs.
FAQs about retatrutide and next-generation GLP-1 drugs
Is retatrutide stronger than Ozempic?
Based on Phase 2 data, retatrutide produced greater average weight loss than semaglutide did in its major obesity trials, with around 22–24% weight loss at 48 weeks versus about 14–15% at 68 weeks for semaglutide 2.4 mg. There are no direct head-to-head trials, so we cannot say this definitively, but the early signal is that retatrutide is more potent.
Is retatrutide FDA-approved yet?
No. Retatrutide is still investigational. It is being studied in Phase 2 and Phase 3 trials for obesity, type 2 diabetes, and MASLD, and is not approved for general clinical use.
Can I get retatrutide from a compounding pharmacy or research supplier?
You should not. The FDA has issued alerts and warning letters about unapproved GLP-1 products, including items marketed as semaglutide, tirzepatide, or retatrutide that are sold “for research use only” but clearly intended for injection. These products are of unknown quality and may be unsafe.
What makes retatrutide different from other GLP-1 drugs?
Retatrutide is a triple agonist that activates GLP-1, GIP, and glucagon receptors together. This appears to produce larger and faster weight loss by combining reduced appetite, better insulin response, and increased energy expenditure from glucagon receptor activation.
Does retatrutide help fatty liver disease?
Early data in people with obesity and MASLD show that retatrutide can reduce liver fat deeply, with up to 82% relative reduction in some participants, along with improvements in liver enzymes and metabolic markers. More research is needed, but this is a promising signal. PubMed+2nature.com+2
Are side effects worse with retatrutide than with semaglutide or tirzepatide?
So far, side effects look similar in type (mostly gastrointestinal) but higher potency often means more symptoms during titration, especially at higher doses. Larger Phase 3 safety datasets will give a clearer picture.
Will retatrutide replace other GLP-1 therapies?
Probably not. Some people respond very well to semaglutide or tirzepatide and may not need a triple agonist. Retatrutide will likely be one option in a spectrum of weight-loss and metabolic medications, not an automatic replacement for everything else.
How to build a full metabolic plan around GLP-1s
Whether the medication is semaglutide, tirzepatide, or a future drug like retatrutide, the model that gets the best long-term outcome is the same:
- Diagnose, do not guess
- Use comprehensive labs to understand insulin resistance, liver health, hormones, inflammation, and nutrient status.
- Protect muscle mass
- Prioritize strength training and protein intake from day one.
- GLP-1 drugs reduce appetite; without planning, you risk losing muscle along with fat.
- Support the liver and gut
- MASLD, dysbiosis, and gut inflammation often travel with obesity and metabolic disease.
- Addressing them improves how you respond to any weight-loss drug.
- Treat hormones as part of the same system
- Thyroid, sex hormones, and cortisol all interact with weight regulation and energy.
- Ignoring them while using GLP-1s is a missed opportunity.
- Design a maintenance phase from the start
- The goal is not just to lose 20–25% of body weight; it is to keep it off.
- That requires lifestyle infrastructure, ongoing lab monitoring, and a clear plan for dose adjustments and long-term follow-up.
This is the type of framework 1st Optimal uses now, and it is the framework that will make or break the real-world impact of retatrutide when and if it is approved.
Conclusion and next steps:
Retatrutide is a preview of what comes next: multi-target metabolic drugs that can deliver bariatric-level weight loss in an injection.
The science so far shows:
- Around 22–24% average weight loss in under a year in Phase 2 obesity trials.
- Clinically meaningful improvements in A1c and weight in people with type 2 diabetes.
- Deep reductions in liver fat and improved markers in MASLD.
At the same time:
- It is not approved yet.
- Long-term safety and durability still need to be proven.
- Illegal and unregulated versions already exist on the gray and black markets, which carry serious risk.
If you are a high-performing adult 35–55 who has been fighting stubborn weight, fatigue, or metabolic issues, your next move is not to chase unapproved research chemicals. It is to get a complete, lab-driven evaluation and use current, approved tools in a structured way.
Ready to understand your options?
- Book a personalized consult with a 1st Optimal provider to review your hormones, gut, metabolic markers, and potential GLP-1 options.
- Build a plan that protects your muscle, your metabolism, and your long-term health, with room to integrate future therapies like retatrutide once they are safe, legal, and ready.
References:
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023.
- Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, in people with type 2 diabetes. The Lancet. 2023.
- Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024.
- Eli Lilly. Phase 2 retatrutide results published in The New England Journal of Medicine. Company press release, June 2023.
- 2 Minute Medicine. Retatrutide effectively reduces body weight in patients with obesity. September 2023.
- AccessMedicine summary on retatrutide obesity trial.
- Gerti Tashko MD. Retatrutide: A Promising Breakthrough for Fatty Liver Disease. 2024.
- JoinVoy. Can Retatrutide Help with Fatty Liver Disease? 2025.
- American Diabetes Association news: Retatrutide results show substantial weight reduction. 2023.
- FDA. Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2025. U.S.
- FDA warning letter regarding compounded retatrutide and GLP-1 products. 2025.
- American Board of Cosmetic Surgery. What Patients Need to Know About the GLP-1 FDA Policy Changes. 2025.
- UCHealth. What to do about fake weight loss drugs and the ban on compounded versions. 2025.
- Health.com. FDA ban on compounded Ozempic and Wegovy as shortage ends. 2025.
- Media report on black-market sale of retatrutide as an unapproved weight loss drug in Ireland.
